For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231006:nRSF9818Oa&default-theme=true
RNS Number : 9818O Citigroup Global Markets Inc. 06 October 2023
Ap38
FORM 38.5(b) (EPT/NON-RI)
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE
UNDER RULE 38.5(b) AND RULE 38.6 OF THE IRISH TAKEOVER
PANEL ACT, 1997, TAKEOVER RULES, 2022 BY A CONNECTED
EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED
INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
(a) Name of exempt principal trader: Citigroup Global Markets Inc.
(b) Name of offeror/offeree in relation to whose relevant securities this Horizon Therapeutics plc
form relates:
Use a separate form for each offeror/offeree
(c) Name of the party to the offer with which exempt principal trader is Amgen Inc.
connected:
(Note 1)
(d) Date position held/dealing undertaken: 05 October 2023
For an opening position disclosure, state the latest practicable date prior to
the disclosure
(e) In addition to the company in 1(b) above, is the exempt principal N/A
trader also making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class
of relevant securities of the offeror or offeree named in 1(b), copy table 2
for each additional class of relevant security.
Ap39
Interests and short positions in the relevant securities of the offeror or
offeree to which the disclosure relates following the dealing (if any) (Note
2)
Class of relevant security: $0.0001 ordinary shares
(Note 3)
Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 201,131 0.0879% 20,750 0.0091%
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to
purchase/ sell:
Total: 201,131 0.0879% 20,750 0.0091%
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any
open stock-settled derivative positions (including traded options), or
agreements to purchase or sell relevant securities, should be given on a
Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
(Note 4)
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in. The
currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of Purchases/ Total Highest Lowest
relevant sales number of price per price per
security securities unit paid/ unit paid/
received (USD) received (USD)
$0.0001 ordinary shares 50,698
Purchase 116.3000 116.3000
$0.0001 ordinary shares 107,961
Sales 116.3000 116.3000
Ap40
(b) Cash-settled derivative transactions
Class of Product Nature of dealing Number of Price per
relevant description e.g. opening/closing reference unit
security e.g. CFD a long/short position, securities (Note 6)
increasing/reducing a (Note 5)
long/short position
(c) Stock-settled derivative transactions (including
options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type Expiry Option
relevant description purchasing, securities price per e.g. date money
security e.g. call
selling, to which
unit American, European paid/
option varying option etc. received
etc. relates per unit (EUR)
(Note 5)
(ii) Exercise
Class of Product Exercising/ Number of Exercise
relevant
description
exercised
securities
price per
security e.g. call
against
unit (Note 6)
option
(d) Other dealings (including transactions in respect of
new securities)
Class of Nature of Details Price per unit
relevant dealing (if applicable)
security e.g. subscription, (Note 6)
conversion,
exercise
Ap41
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may
be an inducement to deal or refrain from dealing entered into by the exempt
principal trader making the disclosure and any party to the offer or any
person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there
are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to
options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should be
stated.
(c) Attachments
Is a Supplemental Form 8 attached? YES/NO
Date of disclosure: 06 October 2023
Contact name: Christopher Alexander Pollock
Telephone number: 02895 954 053
Public disclosures under Rule 38 of the Rules must be made to a Regulatory
Information Service.
Ap42
NOTES ON FORM 38.5(b) AND 38.6
1. See the definition of "connected principal trader"
in Rule 2.2 of Part A of the Rules.
2. See the definition of "interest in a relevant
security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of
Part B of the Rules.
3. See the definition of "relevant securities" in Rule
2.1 of Part A of the Rules.
4. See the definition of "dealing" in Rule 2.1 of Part
A of the Rules.
5. See Rule 2.5(d) of Part A of the Rules.
6. If the economic exposure to changes in the price of
securities is limited, for example, by virtue of a stop loss arrangement
relating to a spread bet, full details must be given.
7. If details included in a disclosure under Rule 38
are incorrect, they should be corrected as soon as practicable in a subsequent
disclosure. Such disclosure should state clearly that it corrects details
disclosed previously, identify the disclosure or disclosures being corrected,
and provide sufficient detail for the reader to understand the nature of the
corrections. In the case of any doubt, the Panel should be consulted.
For full details of disclosure requirements, see Rules 8 and 38 of the Rules.
If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish Takeover Panel Act,
1997, Takeover Rules, 2022.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ITPVQLBBXBLFFBD